Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT05585606
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Silver Creek Pharmaceuticals
- Registry
-
NCT05585606
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05585606. Randomized; quadruple masking; primary purpose treatment. Start 2022-10-19 (actual); primary completion 2025-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
- Acronym
- ARPEGGIO
- Condition
- Acute Ischemic Stroke (AIS)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- scp776 (1.9 mg/kg)
- Intervention (Drug)
- scp776 (3.8 mg/kg)
- Intervention (Drug)
- scp776 (4.8 mg/kg)
- Intervention (Drug)
- scp776 (all dose levels)
- Lead sponsor
- Silver Creek Pharmaceuticals
Record details
- Record id
cardio:ct-nct05585606- Content hash
8febfdc3f58378f932a3b54b3d3a6d714f6a5f9d523f89eb2f989d2578934d31